SLC5A2 and diabetes mellitus: In a similar trend, DPP-4 inhibitors like sitagliptin have been suggested effective and safe for DM patients complicated by liver injuries [14], whereas the second-line therapies GLP-1 receptor agonists and SGLT-2 inhibitors exhibit positive impact on body weight with reduced risk of hypoglycemia.